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Cancer immunotherapy with human cd T cells expressing Vc2Vd2 T cell receptor
(also termed Vc9Vd2) has shown promise because of their ability to recognize and
kill most types of tumors in a major histocombatibility complex (MHC) -unrestricted
fashion that is independent of the number of tumor mutations. In clinical trials,
adoptive transfer of Vc2Vd2 T cells has been shown to be safe and does not
require preconditioning. In this report, we describe a method for preparing highly
enriched human Vc2Vd2 T cells using the bisphosphonate prodrug, tetrakis-pivaloy-
loxymethyl 2-(thiazole-2-ylamino)ethylidene-1,1-bisphosphonate (PTA). PTA stimu-
lated the expansion of Vc2Vd2 cells to purities up to 99%. These levels were
consistently higher than those observed after expansion with zoledronic acid, the
most commonly used stimulator for clinical trials. Cell numbers also averaged more
than those obtained with zoledronic acid and the expanded Vc2Vd2 cells exhibited
high cytotoxicity against tumor cells. The high purity of Vc2Vd2 cells expanded by
PTA increased engraftment success in immunodeficient NOG mice. Even low levels
of contaminating ab T cells resulted in some mice with circulating human ab T cells
rather than Vc2Vd2 cells. Vc2Vd2 cells from engrafted NOG mice upregulated
CD25 and secreted tumor necrosis factor-a and interferon-c in response to PTA-
treated tumor cells. Thus, PTA expands Vc2Vd2 T cells to higher purity than
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zoledronic acid. The high purities allow the successful engraftment of immunodefi-
cient mice without further purification and may speed up the development of allo-
geneic Vc2Vd2 T cell therapies derived from HLA-matched normal donors for
patients with poor autologous Vc2Vd2 T cell responses.
K E YWORD S
adoptive cancer immunotherapy, bisphosphonate, farnesyl diphosphate synthase, Vc2Vd2 T
cells, zoledronic acid
1 | INTRODUCTION
Recent advances in cancer immunotherapy have revolutionized treat-
ment for a number of cancers. By targeting checkpoint receptors,
durable remissions have been achieved in patients with advanced
metastatic melanoma, non-small cell lung cancer (NSCLC), bladder
cancer and kidney cancer that would have had little chance of sur-
vival with conventional chemotherapies or targeted therapies. Simi-
larly, chimeric antigen receptor-T cells (CAR-T) bearing receptors
specific for CD19 have successfully treated patients with relapsing
B-cell acute lymphoblastic leukemia and diffuse large B-cell lym-
phoma. However, both these treatments have limitations. Check-
point blockade targeting PD-1 or its ligand, PD-L1, provides clinical
benefits for a minority of the patients; approximately 30% for mela-
noma and kidney cancer and approximately 20% for lung cancer.1,2
Moreover, the effectiveness of checkpoint blockade correlates with
the numbers of nonsynonymous mutations present in the tumors
from patients with NSCLC3 and melanoma.4 Thus, patients with can-
cers that have low numbers of mutations, such as many of the pedi-
atric cancers and glioblastomas,5 would be predicted to respond
infrequently as has been observed.6 CAR-T therapy is limited
because there are few clearly defined tumor-specific antigens on
solid tumors.7 Therefore, additional types of immunotherapy are
needed to realize the full potential of cancer immunotherapy.
Adoptive immunotherapy with Vc2Vd2 T cells (also termed
Vc9Vd2) is a potential therapy for a variety of cancers and is inde-
pendent of the mutational status of the tumor. Stimulation of
Vc2Vd2 T cells is not dependent on peptides presented by MHC
proteins and is, therefore, major histocombatibility complex (MHC) -
unrestricted.8 Instead, Vc2Vd2 T cells respond to the presence of
small isoprenoid metabolites, such as self isopentenyl pyrophosphate
(IPP)9 or foreign microbial (E)-4-hydroxy-3-methylbut-2-enyl
pyrophosphate (HMBPP),10,11 in a process requiring the butyrophilin
3A1 (BTN3A1) protein, an immunoglobulin superfamily protein pre-
sent on all normal and tumor cells.12-14 The isoprenoid metabolites
bind to the B30.2 intracellular domains of BTN3A1,15,16 which alters
the cell through an unknown process to allow the Vc2Vd2 TCR17 to
recognize this intracellular binding. TCR recognition leads to the acti-
vation of Vc2Vd2 T cells for cytotoxicity and cytokine secretion.
In 9 clinical trials involving a total of 213 patients, adoptive
transfer of Vc2Vd2 T cells18-26 has proven to be safe,20,21 does not
require pretreatment with cytotoxic agents, and has resulted in a
durable remission in a patient with metastatic clear cell renal
cancer,27 complete and partial responses in patients with breast and
cervical cancer,20 and stable disease in 50% of patients with
advanced NSCLC.28 However, most patients progressed, underscor-
ing the need for improvements in the efficacy of this therapy.
The most successful adoptive transfer cd trials gave the nitro-
gen-containing bisphosphonate zoledronic acid (Zol) prior to the
transfer of the cells.20,21 Bisphosphonates indirectly stimulate
Vc2Vd2 T cells by inhibiting farnesyl diphosphate synthase (FDPS),
resulting in the subsequent intracellular accumulation of its sub-
strate, isopentenyl pyrophosphate (IPP), which is bound by
BTN3A1.29,30
Bisphosphonates enter cells through fluid-phase endocytosis and
uptake can be enhanced by Ca2+, suggesting that the negatively
charged P-C-P structure limits entry.31 To improve cellular uptake
and activity, we recently synthesized a bisphosphonate prodrug, tet-
rakis-pivaloyloxymethyl 2-(thiazole-2-ylamino)ethylidene-1,1-bispho-
sphonate (PTA), where these negative charges are masked with
pivoxil esters.32,33 PTA is highly hydrophobic, allowing its efficient
entry into cells where intracellular esterases convert it to its active
acid form that blocks FDPS. PTA is a highly potent inhibitor of
tumor cell proliferation that is 796-fold more potent against
hematopoietic tumors and 27-fold more potent against solid tumors
than Zol (the most potent bisphosphonate in current use).32 Similarly,
PTA efficiently stimulates Vc2Vd2 T cells to secrete TNF-a with 75
different tumor cell lines, being 903-fold more potent on average
than Zol.33
In this study, we examine the effect of the PTA bisphosphonate
prodrug on the expansion of peripheral blood Vc2Vd2 T cells ex vivo
from patients with prostate cancer and breast cancer and analyze
the engraftment success and effector functions of the expanded
Vc2Vd2 T cells after adoptive transfer to immunodeficient NOG
mice.
2 | MATERIALS AND METHODS
2.1 | Reagents
Tetrakis-pivaloyloxymethyl 2-(thiazole-2-ylamino)ethylidene-1,1-
bisphosphonate (PTA) and 2-(thiazole-2-ylamino)ethylidene-1,1-
bisphosphonate (TA) were synthesized as described.32 Zoledronic
acid (Zol) was purchased from Novartis AG (Basel, Switzerland). (E)-
4-hydroxy-3-methylbut-2-enyl pyrophosphate (HMBPP) was synthe-
sized as described.34
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2.2 | Solubilization of PTA
PTA (10 lmoles) was dissolved in 10 mL of either DMSO or ethanol
containing 10 mM of trimethyl b-cyclodextrin (TMbCD). TMbCD, a
cyclic compound composed of 7 trimehtyl-D-glucopyranoside units
linked a1>4, was synthesized as described.35
2.3 | Expansion of Vc2Vd2 T cells
Blood was obtained from healthy adult donors and prostate and
breast cancer patients following approval by the institutional
review board of Kyoto University and the Tokyo Women’s Medi-
cal University and written informed consent being provided by
patients. Patients’ characteristics are summarized for prostate can-
cer patients in Table S1 and for breast cancer patients in
Table S2. Peripheral blood mononuclear cells (PBMC) were purified
by Ficoll-Paque PLUS (GE Healthcare Bio-Sciences AB, Uppsala,
Sweden) gradient centrifugation. The cells were washed 2 times
with PBS, then resuspended in modified Yssel’s medium supple-
mented with 10% human AB serum (Cosmobio, Koto-ku, Tokyo,
Japan) or enriched RPMI 1640 medium.36 They were cultured at
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F IGURE 1 Structure and immunological
activity of bisphosphonates. A, Structure of
the bisphosphonate prodrug, PTA, its
active acid form, TA, and zoledronic acid
(Zol). B, Effect of bisphosphonates on the
aggregation of Vc2Vd2 T cells in peripheral
blood mononuclear cells (PBMC). PBMC
from a healthy donor where Vd2 T cells
constituted 20.2% of total T cells, were
exposed to varying concentrations of the
bisphosphonates for 2 days, and cell
aggregation was monitored under a
microscope. C, TNF-a production by
PBMC in response to bisphosphonates.
After incubation of PBMC with
bisphosphonates for 2 days, supernatants
were harvested and TNF-a levels
measured by ELISA
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5 lM TA or 5 lM ZOL in the presence of 100 U/mL interleukin-
2 (IL-2) (Shionogi Pharmaceutical, Chuo-ku, Osaka, Japan) in
4 wells of a 24-well plate (Corning Incorporated, Corning, NY).
The culture medium was replaced every day from day 2 to day 9
with fresh medium containing IL-2. On day 10 for Yssel’s media
or on day 14 for RPMI 1640 media, the cells were harvested. Pur-
ity of the Vc2Vd2 T cells were assessed by flow cytometry and
the cells were either directly transferred or frozen in liquid nitro-
gen for later use.
2.4 | Statistical analysis
Statistical analyses were performed in GraphPad Prism v7.0A using
the non-parametric 2-tailed Wilcoxon signed rank test for paired
samples. P-values are as given with values <.05 considered
significant.
2.5 | Cell aggregation assay
Cell aggregation during the culture was recorded under a microscope
(Eclipse TS100, Nikon, Minato-ku, Japan) equipped with a digital
camera (CoolPIX L20, Nikon).
2.6 | Flow cytometric analysis
Peripheral blood mononuclear cells before and after expansion
were plated out at 2 9 105 cells/50 lL in a 96-well plate (Corn-
ing Incorporated, Corning, NY). The cells were then treated with
3 lL of FITC-conjugated anti-TCR Vd2 mAb (clone IMMU 389,
Beckman Coulter, Flullerton, CA, USA) and phycoerythrin (PE)-
conjugated anti-CD3 mAb (clone SK7, BD Biosciences, San
Diego, CA, USA) on ice for 30 min. After being washed 3 times
with PBS, the cells were resuspended in 200 lL of 1%
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F IGURE 2 Expansion of Vc2Vd2 T cells
by PTA or Zol. PBMC derived from a (A)
healthy adult donor or a (B) breast cancer
patient (BC37B) were stimulated either by
PTA or Zol with interleukin-2 (IL-2) in
either enriched RPMI 1640 (panel A) or
Yssel’s media (panel B) for 10 days and
then analyzed by flow cytometry
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paraformaldehyde in PBS and analyzed using a FACSCalibur or
an LSR II flow cytometer (Becton Dickinson, Franklin Lakes, NJ,
USA).
2.7 | TNF-a production by peripheral blood
mononuclear cells in response to bisphosphonates
Peripheral blood mononuclear cells derived from a healthy adult
donor were cultured for 24 h at 2.5 9 106 cells/1.5 mL in modified
Yssel’s medium with 1 lM PTA, 5 lM TA or 5 lM Zol in the pres-
ence of 100 U/mL IL-2 in a 24-well plate. The culture medium was
removed and the content of TNF-a was determined using the stan-
dard ELISA according to the manufacturer’s protocol (Peprotech,
Rocky Hill, NJ, USA).
2.8 | Cytotoxicity assay
Peripheral blood mononuclear cells from 2 healthy adult volunteers
were stimulated with 1 lM PTA and IL-2. On day 11, the proportion
of Vc2Vd2 T cells among CD3 T cells was confirmed to be greater
than 99%. Vc2Vd2 T cell-mediated cellular cytotoxicty against tumor
cells was determined using a non-radioactive cellular cytotoxicity
assay according to the manufacturer’s protocol (Techno Suzuta,
Heiwa-machi, Nagasaki, Japan). In brief, RPMI8226 (a plasmacytoma
cell line that directly stimulates Vc2Vd2 T cells), K562 (an ery-
throleukemic cell line that is sensitive to killing by natural killer (NK)
cells and to NK-like killing by T cells) and PTA-pretreated U937 (a
monocyte-like histiocytic lymphoma cell line) were incubated with
the europium-chelate-forming compound, bis(butyryloxymethyl) 40-
hydroxymethyl-2,20:60 ,2″-terpyridine-6,6″-dicarboxylate, for 15 min
at 37°C.37 After being washed with RPMI 1640 medium, the tumor
cells were incubated with PTA-expanded Vc2Vd2 T cells at effector
to target ratios of 0, 0.625, 1.25, 2.5, 6, 10, 20 and 40. The cells
were centrifuged and after 40 min, the culture supernatants har-
vested and mixed with a europium solution to form a europium-che-
late complex with released labeling compound. Time-resolved
europium fluorescence was measured on a PHERAStar FS multiplate
reader (BMG LABTECH GmbH, Allmendgruen, Ortenberg, Germany)
or a Berthold multiplate reader (Berthold Technologies GmbH, KG,
Bad Wildbad, Germany).
2.9 | Adoptive transfer of Vc2Vd2 T cells into
immunodeficient NOG mice
Peripheral blood mononuclear cells derived from healthy donors or
prostate cancer patients were stimulated with 1 lM of PTA and IL-
2 as detailed above and harvested on day 10 for direct transfer
(for healthy donors) or frozen for later use (for cancer patients).
Vc2Vd2 T cells constituted >98% of lymphocytes. Vc2Vd2 T cells
from healthy donors were transferred directly, whereas Vc2Vd2 T
cells from cancer patients were thawed, washed and then trans-
ferred. For both types of donors, 5 9 107 Vc2Vd2 T cells were i.p.
injected into immunodeficient NOD.Cg-Prkdcscid I12rgtm1Sug/Jic
(NOG) mice (Central Institute for Experimental Animals, Kawasaki,
Kanagawa, Japan) that were maintained under specific-pathogen-
free conditions. Fourteen or fifteen days later, peripheral blood was
obtained and the red blood cells (RBC) were lysed with 1 mL of
F IGURE 3 Expansion of Vc2Vd2 T cells by PTA increases their
purity and number compared with expansion by Zol. Vc2Vd2 T cells
were expanded from peripheral blood mononuclear cells (PBMC)
derived from patients with prostate or breast cancer by either PTA
or Zol. PBMC were cultured with PTA or Zol in the presence of
interleukin-2 (IL-2) for 10 days and then analyzed before and after
by flow cytometry. A, Purity of Vc2Vd2 T cells expanded by PTA or
Zol. Vc2Vd2 T cells averaged 5.3% higher purity (ranging from 1.4 to
14.4%) (95.6  5.7% of total cells for PTA vs 90.3  10.0% for Zol,
P = .0078). The starting percentage of Vc2Vd2 T cells of total T cells
is listed for each patient at the top of the panel. The mean  SD
was 3.1  1.6% for the patients versus 2.9  3.9% for normal
adults as determined in an earlier study.49 B, Number of Vc2Vd2 T
cells expanded by PTA or Zol. Cell numbers averaged 30% higher
with PTA compared to Zol. Vc2Vd2 T cells expanded on average to
5.6 9 108  5.8 9 108 cells with PTA versus
4.3 9 108  3.7 9 108 cells with Zol (P = .20, not significant). (c)
Fold increase of Vc2Vd2 T cells expanded by PTA or Zol. PTA
expansion compared to Zol ranged from 0.5 to 1.9-fold different
(7085-fold for PTA vs 4936-fold for Zol, P = .25, not significant). BC,
breast cancer; PC, prostate cancer
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ACK lysis buffer (8.024 g of NH4Cl, 1.001 g of KHCO3 and
3.722 mg of EDTA/Na2/2H2O in 1000 mL of Milli-Q water). After
washing with PBS/2% FCS, the resulting cells were stained with
FITC-conjugated anti-Vd2 TCR and PE-conjugated anti-human
CD3 mAb. Animal use was approved by the institutional review
board of Kyoto University Medical School. All experiments were
performed in accordance with the relevant guidelines and regula-
tions of Kyoto University Medical School.
2.10 | TNF-a production by adoptively transferred
Vc2Vd2 T cells in vitro
NOG mice were i.p. injected with 5 9 107 Vc2Vd2 T cells from a
breast cancer patient (BC21). Two weeks later peripheral blood was
taken from the mice, RBC were lysed with ACK buffer, and the
resulting peripheral blood cells were stimulated with 1 lM of
HMBPP at a cell concentration of 1 9 105 cells/100 lL in vitro.
After 24 h, the culture supernatants were harvested and TNF-a
levels were determined in triplicate by ELISA (Peprotech, Rocky Hill,
NJ, USA).
2.11 | CD25 expression on adoptively transferred
Vc2Vd2 T cells stimulated in vivo
NOG mice were i.p. injected with 1 9 106 EJ-1 cells. Four weeks
later the mice were i.p. injected with 1 9 107 Vc2Vd2 T cells and
1 lg of PTA. Vc2Vd2 T cells were harvested 24 h after the injection
and stained with PE-conjugated anti-human CD25 mAb (clone BC96,
Biolegend, San Diego, CA, USA).
2.12 | Determination of IFN-c mRNA in adoptively
transferred Vc2Vd2 T cells stimulated in vivo
NOG mice were i.p. injected with 1 9 106 EJ-1 cells. Four weeks
later, the mice were i.p. injected with 1 9 107 Vc2Vd2 T cells with
or without 1 lg of PTA. Peripheral blood was taken from the mice
4 h and 24 h after the challenge, and human IFN-c mRNA levels
measured in the harvested cells by quantitative PCR. Total RNA was
purified using an RNeasy Mini Kit (Qiagen, Valencia, CA, USA) and
complementary DNA was synthesized from 1 lg of total RNA using
SuperScript III reverse transcriptase kit and random hexamers






















F IGURE 4 Expansion of Vc2Vd2 T cells
from prostate cancer patients by PTA leads
to high purity. Peripheral blood
mononuclear cells (PBMC) isolated from
prostate cancer patients were analyzed by
flow cytometry before (left panels) and
after (right panels) stimulation with PTA
and interleukin-2 (IL-2) for 10 days. Values
shown are % of CD3 T cells. The absolute
number of Vd2 T cells increased from
2.0 9 105 to 2.4 9 108 for PC01,
5.7 9 105 to 6.4 9 108 for PC02, and
1.7 9 105 to 7.6 9 108 for PC03, with the
expansion rate being 1175-fold for PC01,
1118-fold for PC02, and 4398-fold for
PC03
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(Invitrogen, Carlsbad, CA, USA). Then, RT-PCR was performed using
a 0.2 lM concentration of both forward and reverse primers and
iTaq SYBR Green Supermix with ROX (Bio Rad, Hercules, CA, USA).
The quantity of each cDNA was normalized by GAPDH. The
following PCR primers were used for amplification: IFN-c,
50- TGACCAGAGCATCCAAAAGA-30 and 50-CTCTTCGACCTCGAAA
CAGC-30; GAPDH, 50- CGACCACTTTGTCAAGCTCA -30 and 50-AGG
GGAGATTCAGTGTGGTG -30.
2.13 | IFN-c production by adoptively transferred
Vc2Vd2 T cells stimulated in vivo
NOG mice were i.p. injected with 1 9 106 EJ-1 cells. Four weeks
later the mice were further i.p. injected with 1 9 107 Vc2Vd2 T cells
with or without PTA. Peripheral blood was taken from the mice 4 h
and 24 h after the injection, serum was prepared, and serum IFN-c
levels were measured by ELISA (Peprotech, Rocky Hill, NJ).
3 | RESULTS
3.1 | Delivery of PTA in an inclusion complex with
trimethyl b-cyclodextrin
We recently described a new thiazole bisphosphonate prodrug,
PTA, that is highly active relative to its acid form, TA, and to Zol
(the most potent bisphosphonate in clinical use) (structures shown
in Figure 1A).32,33 PTA is highly hydrophobic and is insoluble in
water or ethanol. Although PTA can be dissolved in DMSO for
research use, few drugs solubilized in DMSO have been approved
for use in patients. Therefore, we tested a number of nonionic
detergents for their ability to solubilize PTA in ethanol. A tri-
methyl derivative of b-cyclodextrin (TMbCD) had the best ability
to solubilize PTA in ethanol (Figure S1). Cyclodextrin compounds
can form inclusion complexes with drugs where hydrophobic drugs
bind to their central hydrophobic cavity and where the polar sur-
face of cyclodextrin makes the complex soluble in ethanol.38,39
PTA could be dissolved up to a concentration of 1 mM in ethanol
containing 10 mM of TMbCD. Importantly, PTA solubilized in
TMbCD/ethanol exhibited identical bioactivity to PTA solubilized
in DMSO. For example, PTA in TMbCD/ethanol inhibited the pro-
liferation of the EJ-1 bladder carcinoma and the U937 histocy-
toma cell lines identically to PTA in DMSO (Figure S1C,D). Thus,
TMbCD/ethanol can be used as the solvent for PTA, as was done
in this study.
3.2 | Stimulation of Vc2Vd2 T cells by PTA
PTA potently inhibits the growth of tumor cell lines in vitro32 and
selectively activates Vc2Vd2 T cells in PBMC to proliferate,
secrete cytokines and kill tumor cells.33 Consistent with these
results, when we compared the activity of Zol to the PTA prodrug
and its TA acid form, PTA was strongly active. Zol and TA stimu-
lated Vc2Vd2 T cell-dependent cell aggregation at concentrations
of approximately 10 lM, whereas PTA caused aggregation at
approximately 0.1 lM (Figure 1B). Similarly, PTA stimulated TNF-a
production by Vc2Vd2 T cells at an EC50% of 3 nM, whereas TA
and Zol stimulated at an EC50% of 3000 nM (Figure 1C). Thus,
PTA was 1000-fold more potent than TA and Zol in stimulating
Vc2Vd2 T cells in PBMC.
3.3 | Ex vivo expansion by PTA of Vc2Vd2 T cells
for adoptive immunotherapy
To determine whether PTA can be used to expand Vc2Vd2 T
cells for adoptive immunotherapy, PMBC from cancer patients
and from healthy donors were stimulated with PTA and IL-2 and
the resulting Vc2Vd2 T cells were assessed for purity and biolog-
ical activity after 10 days. Similar to what we have previously
F IGURE 5 Cytotoxic activity of PTA-expanded Vc2Vd2 T cells
against tumor cells. A, Cytotoxicity of PTA-expanded Vc2Vd2 T cells
against K562 and RPMI 8226 tumor cells. K562 erythroleukemia
cells (right panel) and RPMI 8226 plasmacytoma cells (left panel)
were labeled with a europium-chelate-forming procompound,
washed, and then incubated with PTA-expanded Vc2Vd2 T cells at
effector to target ratios of 0, 0.625, 1.25, 2.5, 5, 10, 20 and 40 for
40 min at 37°C in a 5% CO2 incubator. The culture supernatants
were combined with an europium solution and the levels of the
europium–chelate complex determined by measuring time-resolved
fluorescence. Specific lysis (%) was calculated as [(experimental
release  spontaneous release)/(maximum release  spontaneous
release)]9 100. All assays were performed in triplicate. B,
Cytotoxicity of PTA-expanded Vc2Vd2 T cells against PTA-pulsed
U937 histiocytic lymphoma cells. U937 cells were either not treated
(open circles) or treated with 500 nM PTA (solid circles) at 37°C
with 5% CO2 for 2 h followed by labeling and testing for specific
lysis as detailed in (A)
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shown for Zol,36 PTA stimulated maximum expansion within a
relatively narrow dose range when PBMC were continuously
exposed to PTA as it was slowly diluted (Figure 2). Thus, Vc2Vd2
T cell expansion was maximal at a PTA concentration of 1 lM,
while a PTA concentration of 2 lM was highly toxic (Figure 2A).
PTA stimulation resulted in highly enriched populations of
Vc2Vd2 T cells that approached 100% of CD3 T cells, whereas
Zol stimulation was consistently less (Figure 2A,B). To determine
the effect of PTA on Vc2Vd2 T cells from cancer patients,
PBMC from 8 cancer patients with prostate or breast cancer
were stimulated with either PTA or Zol (Figure 3). PTA stimula-
tion resulted in significantly higher enrichment of the Vc2Vd2 T
cell population as compared with Zol stimulation (95.6  5.7% of
total cells vs 90.3  10.0%, P = .0078, Figure 3A). All donors
exhibited higher enrichment with PTA compared to Zol. In addi-
tion, the number of Vc2Vd2 T cells was 20% higher on average
for stimulation with PTA as compared with Zol
(6.3 9 108  5.5 9 108 cells with PTA vs 5.7 9 108  4.3 9 108
cells with Zol, P = .38, Figure 3B), although this was observed for
only 6 out of 8 patients and was not statistically significant. The
increase in Vc2Vd2 cell numbers varied widely ranging from 959
to 28 722-fold (6344-fold for PTA vs 4302-fold for Zol, P = .31)
and was not significantly different (Figure 3C). Examples of
Vc2Vd2 T cell expansion in response to PTA are shown for pros-
tate cancer patients (Figure 4) and healthy donors (Figure S2).
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F IGURE 6 Adoptively transferred
human Vc2Vd2 T cells from prostate
cancer patients persist in the blood of
NOG mice. Vc2Vd2 T cells (>98%) were
expanded from prostate cancer patient 2
(PC02) (left panels) and patient 4 (PC04)
(right panels) and frozen for later use.
5 9 107 thawed Vc2Vd2 T cells were then
adoptively transferred into each NOG
mice. Fifteen days after transfer, peripheral
blood was obtained. After RBC lysis, the
resulting cells were stained and then
analyzed by flow cytometry for expression
of Vd2 TCR and human CD3. Values
shown are % of total cells. Mean  SD
PC02 2.5%  0.9%, n = 3 PC04
6.4%  2.4%, n = 3
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cancer patients results in Vc2Vd2 T cell populations that were of
significantly higher purity and slightly higher number than when
Zol was used for stimulation.
3.4 | Cytotoxic activity of Vc2Vd2 T cells expanded
by PTA
Adult Vc2Vd2 T cells are highly cytotoxic40 and exhibit cytotoxicity for
most tumor cell lines.8,33 Vc2Vd2 T cells expanded with PTA were,
therefore, assessed for their cytotoxic activity against an NK-sensitive
cell line, a stimulatory plasmacytoma and a tumor cell line treated with
PTA. PTA-expanded Vc2Vd2 T cells exhibited strong NK-like cytotoxic
activity efficiently lysing the NK target cell line, K562, which lacks
MHC class I (Figure 5A). PTA-expanded Vc2Vd2 T cells also lysed the
RPMI 8226 plasmacytoma cell line that is directly stimulatory for
Vc2Vd2 T cells through a TCR-dependent mechanism (Figure 5A).17,41
Finally, PTA-expanded Vc2Vd2 T cells efficiently lysed U937 tumor
cells that had been treated with PTA (Figure 5B). Therefore, expansion
of Vc2Vd2 T cells by PTA preserves their cytotoxic activity.
3.5 | Purity of Vc2Vd2 T cells helps to determine
their engraftment success after adoptive transfer in
NOG mice
To assess their potential use for cancer immunotherapy, Vc2Vd2 T cells
expanded by PTA were adoptively transferred into immunodeficient
NOG mice. Vc2Vd2 T cells expanded from prostate cancer patient 2
(PC02) and 4 (PC04) using PTA with IL-2 (shown in Figure 4) were i.p.
injected into immunodeficient NOG mice and continued to circulate
15 days later. Mice receiving cells from prostate cancer patient 2
(PC02) averaged 2.5% Vc2Vd2 T cells, whereas mice receiving cells
from prostate cancer patient 4 (PC04) averaged 6.4% Vc2Vd2 T cells of
total cells (Figure 6). Similarly, NOG mice receiving Vc2Vd2 T cells
derived from a normal donor averaged 18.8% in Experiment 1 and
12.6% in Experiment 2 (Figure S3), whereas breast cancer patients
averaged 8.8% for BC36 and 4.8% for BC35 (Figure S4). The higher pro-
portions of Vc2Vd2 T cells observed with the normal donor were likely
due to the transfer of freshly expanded Vc2Vd2 T cells instead of the
previously frozen cells used from prostate and breast cancer patients.
Transfer of highly enriched Vc2Vd2 T cells (>98% of total cells)
reduced the proportion of NOG mice with elevated levels of ab T cells
(Figure 7A,B). For example, transfer of Vc2Vd2 T cells expanded using
Zol from patient BC35 which were 90% pure resulted in only 1 out of
9 NOG mice having Vc2Vd2 T cells that constituted greater than 80%
of circulating T cells while transfer of Vc2Vd2 T cells which were 97%
pure resulted in only 1 out of 5 NOG mice (Figure S4). In contrast,
transfer of Vc2Vd2 T cells with purities >98% resulted in 29 out of 32
NOG mice with Vc2Vd2 T cells constituting greater than 80% of circu-
lating T cells (Figure 7A, lower panel). Thus, the high purity of Vc2Vd2
T cells expanded using PTA helped to ensure successful engraftment
of NOG mice without ab T cell outgrowth.
3.6 | Adoptively transferred Vc2Vd2 T cells from
NOG mice are fully functional
To assess the functional capabilities of Vc2Vd2 T cells expanded by
PTA in vivo, we tested various immunological functions of the cells
F IGURE 7 Purity of Vc2Vd2 T cells helps to determine their
engraftment success after adoptive transfer in NOG mice. A,
Summary of the results of NOG mouse engraftment with expanded
Vc2Vd2 T cells. Top panel: Levels of Vc2Vd2 T cells as a percentage
of total cells for each transfer experiment. Bottom panel: Levels of
Vc2Vd2 T cells as a percentage of T cells for each transfer
experiment. Each point represents 1 NOG mouse. Vc2Vd2 T cells
were expanded using PTA except for BC35 that was expanded using
Zol. Thawed Vc2Vd2 T cells were used for cells derived from cancer
patients whereas freshly expanded Vc2Vd2 T cells were used for the
healthy donor. The purity of the starting populations as a percent of
total cells is listed at the bottom. B, Purity of the starting population
of Vc2Vd2 T cells helps to determine engraftment success. The
purity of the transferred Vc2Vd2 T cells is correlated with the
percentage of NOG mice with predominant Vc2Vd2 T cell
populations (>80%) at 2 weeks. Each data point represents 1
transfer experiment
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after their adoptive transfer to immunodeficient NOG mice. First,
recovered Vc2Vd2 T cells were tested for their ability to secrete
TNF-a. Despite 2 weeks in NOG mice without exogenous human IL-
2 or IL-15, recovered Vc2Vd2 T cells secreted TNF-a upon in vitro
stimulation with the bacterial metabolite, HMBPP (Figure 8A). Note
that murine cells and other human T cells do not respond to HMBPP
or its analogs, as we have shown in earlier studies.11,42
Second, we examined the ability of transferred Vc2Vd2 T cells to
respond to bisphosphonate stimulation in vivo. For these experi-
ments, NOG mice bearing human EJ-1 bladder carcinoma cells were
i.p. injected with Vc2Vd2 T cells with or without PTA and Vc2Vd2 T
cells recovered from the mice 4 h and 24 h later. After 24 h,
Vc2Vd2 T cells upregulated expression of the CD25 IL-2a receptor
when stimulated with PTA (right panel, Figure 8B) but not if PTA
was omitted (left panel, Figure 8B). Moreover, IFN-c mRNA
expression in Vc2Vd2 T cells was upregulated, reaching maximum
levels at 4 h and declining thereafter (Figure 8C). Serum human IFN-
c protein levels increased later such that levels were higher at 24 h
compared with 4 h (Figure 8D), consistent with the requirement for
translation of IFN-c to produce the cytokine rather than its release
from preformed stores as has been demonstrated for in vivo
responses to lymphocytic choriomeningitis virus.43 IFN-c production
was dependent on Vc2Vd2 T cells given that NOG mice bearing EJ-
1 cancer cells with PTA but no Vc2Vd2 T cells or receiving only PTA
alone failed to upregulate IFN-c expression at either the mRNA or
protein levels. These findings clearly demonstrate that adoptively
transferred Vc2Vd2 T cells that have been expanded by PTA stimu-
lation can be specifically activated in vivo with bisphosphonate stim-





F IGURE 8 Functional analyses of
Vc2Vd2 T cells adoptively transferred into
NOG mice. A, TNF-a production by
adoptively transferred Vc2Vd2 T cells from
NOG mice. Three NOG mice were each
i.p. injected with 2 9 107 Vc2Vd2 T cells
derived from a healthy donor. Two weeks
later, peripheral blood cells were collected
and Vc2Vd2 T cells stimulated by HMBPP
in vitro. After 24 h of incubation, culture
supernatants were collected and TNF-a
levels assessed in triplicate. B, Expression
of CD25 on Vc2Vd2 T cells adoptively
transferred into NOG mice bearing EJ-1
bladder cancer tumors treated with PTA.
NOG mice were i.p. injected with EJ-1
tumor cells. Four weeks later, the mice
were i.p. injected with 1 9 107 Vc2Vd2 T
cells with or without PTA. Vc2Vd2 T cells
were harvested 24 h later and CD25
expression assessed by flow cytometry. C,
IFN-c mRNA expression by Vc2Vd2 T cells
adoptively transferred into NOG mice
bearing EJ-1 tumors treated with PTA.
NOG mice were i.p. injected with EJ-1
tumor cells. Four weeks later, the mice
were i.p. injected with 1 9 107 Vc2Vd2 T
cells with or without PTA or PTA alone.
Peripheral blood samples were obtained
4 h and 24 h after the challenge and IFN-c
mRNA levels determined by quantitative
PCR. D, IFN-c production by Vc2Vd2 T
cells adoptively transferred into NOG mice
bearing EJ-1 tumors treated with PTA.
NOG mice were treated as described in
(C). Blood samples were collected 4 h and
24 h after PTA injection, serum prepared
and serum IFN-c levels measured by ELISA
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4 | DISCUSSION
In the present study, we show that PTA, a novel bisphosphonate
prodrug, expands peripheral blood Vc2Vd2 T cells up to several
thousand-fold in 10 days, with very high purity in both cancer
patients and healthy adult donors. PTA is, thus, ideal for the prepara-
tion of large numbers of highly homogeneous Vc2Vd2 T cells for use
in adoptive immunotherapy for cancer. These expanded Vc2Vd2 T
cells exhibited full immunological functions when tested in preclinical
immunodeficient mouse models and their high purity helped to limit
the outgrowth of human ab T cells in these mice.
The pivaloyloxymethyl groups of PTA mask the hydrophilic phos-
phonate moieties, allowing cell entry but also making PTA hydropho-
bic such that it dissolves in DMSO but not in ethanol. Because of the
possible toxicity of DMSO and its chemical properties (high freezing
point and garlic taste), few intravenous drugs are solubilized in DMSO
for patient use. However, because none of the conventional deter-
gents used in clinical practice allowed PTA to dissolve in ethanol, we
tested TMbCD. TMbCD is highly soluble in both water and ethanol
and its parent compound, bCD, has been used for drug delivery. The
less hydrophilic interiors of these compounds allow them to form com-
plexes with hydrophobic drugs. Accordingly, TMbCD solubilizes PTA
in ethanol. This TMbCD/ethanol solubilization method could be appli-
cable to other hydrophobic therapeutics, such as alkoxymethyl deriva-
tives of anionic compounds. PTA dissolved in TMbCD/ethanol
exhibited identical biological activity to PTA dissolved in DMSO, sug-
gesting that PTA preparation in TMbCD/ethanol could be used for
both preclinical and clinical studies.
In previous clinical studies, it was not clear whether IL-2 infusion
was essential for adoptive immunotherapy with cd T cells because
some studies gave IL-2 in vivo. This study clearly shows that Vc2Vd2
T cells continued to circulate in the peripheral blood even 2 weeks
after i.p. injection into NOG mice in the absence of exogenous IL-2.
In addition, the transferred Vc2Vd2 T cells were functionally active,
as evidenced by the expression of TNF-a, CD25 and IFN-c in
response to PTA-sensitized tumor cells or HMBPP stimulation.
Although IL-2 is absolutely required for the maintenance of Vc2Vd2
T cells in vitro, these findings suggest that IL-2 is not absolutely nec-
essary in adoptive immunotherapy with Vc2Vd2 T cells. Thus, IL-2
infusion might be omitted or reduced in patients undergoing adop-
tive cancer immunotherapy with Vc2Vd2 T cells.
Using PTA to expand Vc2Vd2 T cells for adoptive
immunotherapy has potential advantages over Zol, the most com-
monly used stimulator for clinical trials. PTA stimulation consis-
tently resulted in highly enriched populations of Vc2Vd2 T cells
that were of significantly higher purity than those expanded by
Zol. In many cases, Vc2Vd2 T cells were >99% of total T cells
and it may be possible to further increase cell yields by using
pulse PTA stimulation, as we have shown for pulse stimulation
with Zol.36 The ability to generate highly enriched Vc2Vd2 T cells
would be useful for preclinical studies in immunodeficient mice.
Our findings show that relatively low levels of ab T cell contami-
nation can lead to the outgrowth of ab T cells in the mice. This
contamination could lead to xenogeneic graft-versus-host-disease
that is observed when human PBMC are xenotransplanted into
NSG mice and that leads to their deaths with a median survival
of 40 days.44,45 The contamination could also compromise tumor
immunity by Vc2Vd2 T cells through competition with ab T cells.
Our findings suggest that Vc2Vd2 T cells should generally be puri-
fied prior to use in long-term tumor studies in immunodeficient
NSG or NOG mice. Using PTA-expanded Vc2Vd2 T cells as a
starting population would ensure that purification would give
highly enriched Vc2Vd2 T cells with few ab T cells.
Another potential use of such highly enriched populations would
be allogenic adoptive transfer of Vc2Vd2 T cells for tumor
immunotherapy. Thus far, all clinical trials have used syngeneic
Vc2Vd2 T cells. However, because Vc2Vd2 T cells are not
alloreactive and because the BTN3A1 is not polymorphic,46 Vc2Vd2
T cells can be stimulated by allogeneic tumor cells treated with PTA
or a prenyl pyrophosphate. Because they are not alloreactive, trans-
fer of Vc2Vd2 T cells will not cause graft-versus-host disease. Note
that in natural infections, very high numbers of Vc2Vd2 T cells can
be observed (up to 50% of circulating T cells) without autoimmunity
or other toxicity (reviewed in Morita et al.8).
The ability to generate highly enriched Vc2Vd2 T cells prepara-
tions without contaminating ab T cells would allow their use as “off-
the-shelf” reagents for cancer immunotherapy. This would result in
major cost savings and greatly increase the feasibility of such treat-
ments because normal donors that expand particularly well could be
selected and these individuals can be repeatedly leukophoresed to
obtain starting PBMC. To avoid host-versus-graft disease, the donors
could be HLA typed and donors selected based on their degree of
HLA match to the recipient. If host-versus-graft responses develop,
the donor for the Vc2Vd2 T cells could be switched. If necessary, ab
T cells could be depleted using anti-ab TCR magnetic beads as this
process would be very efficient because of their low abundance.
Such an approach is being investigated commercially for CAR-NKT
cells. Moreover, infusion of HLA-matched allogeneic virus-specific
cytotoxic lymphocytes derived by in vitro stimulation is already
being used to treat patients undergoing bone marrow transplantation
who have developed severe viral infections with Epstein–Barr virus
or cytomegalovirus.47 In one study, the transferred cells could be
detected in the blood for a median period of 10 weeks and there
was minimal toxicity.48 The ability to generate large numbers of
highly enriched Vc2Vd2 T cells that can be banked and used as “off-
the-shelf” reagents could greatly facilitate the development of adop-
tive Vc2Vd2 T cell therapies.
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